Cigna earnings beat by $0.04, revenue topped estimates
In the dynamic landscape of exchange-traded funds (ETFs), Cathie Wood’s ARK ETFs continue to make decisive moves in the market. For Thursday, 13 March 2025, the funds managed by Wood’s investment firm executed several significant transactions, reflective of its ongoing investment strategies.
Topping the list of ARK’s daily trades was the sale of UIPATH INC (NYSE:PATH), where a total of 1,101,216 shares were offloaded across the ARKK and ARKW ETFs, culminating in a substantial $13,027,385 in value. This move marks a continued trend of reducing exposure to the automation software company, following a pattern of sales observed in the previous trading days.
Conversely, ARK showed a growing interest in the financial technology and cryptocurrency sectors, with the largest dollar-value purchase being 143,855 shares of ROBINHOOD MARKETS INC (NASDAQ:HOOD) at a value of $5,598,836. This accumulation aligns with ARK’s bullish stance on the online brokerage platform, as seen with consistent buys in recent days.
Another notable investment was in COINBASE GLOBAL INC (NASDAQ:COIN), with ARK adding 29,353 shares through its ARKK ETF for a value of $5,627,850. The purchase signals ARK’s confidence in the cryptocurrency exchange, which has been a recurring theme in the fund’s activity, including a significant buy earlier in the week.
Additional buys included CRISPR THERAPEUTICS AG (NASDAQ:CRSP) with a collective acquisition of 105,974 shares across ARKK and ARKG ETFs, totaling $4,608,809, and GITLAB INC (NASDAQ:GTLB), where 80,975 shares were bought for $4,274,670. These transactions underscore ARK’s commitment to innovative biotechnology and software development companies.
ARK also expanded its holdings in IBOTTA INC (private:IBTA) by purchasing 126,150 shares, distributed between ARKW and ARKF ETFs, amounting to $5,297,038. This move is consistent with the fund’s previous day’s interest in the mobile shopping app company.
Smaller-scale investments included GENIUS SPORTS LTD (NYSE:GENI) and TEMPUS AI INC (private:TEM), with purchases of $152,552 and $1,370,414, respectively. Although these trades represent smaller dollar values, they are part of ARK’s diverse portfolio strategy.
On the selling side, aside from UIPATH INC, ARK also reduced positions in PRIME MEDICINE INC (NASDAQ:PRME), ROBLOX CORP (NYSE:RBLX), and REPARE THERAPEUTICS INC (NASDAQ:RPTX), with sales amounting to $678, $1,161,649, and $14,383, respectively. These sales reflect ARK’s tactical adjustments to its holdings based on performance and strategic outlook.
Investors tracking Cathie Wood’s ARK ETFs can discern a pattern of increasing stakes in companies poised for growth in technology, biotech, and fintech, while strategically divesting in others. This latest report provides a snapshot of ARK’s dynamic investment approach, catering to those interested in the intersection of innovation and finance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.